ArticleFrontiers in immunology2025
Development of nanobody-based DAS-ELISA and Au nanoparticle-based immunochromatographic test strip for highly sensitive detection of Chikungunya virus.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Overview of Chikungunya Virus Pathogenesis, Genome Variation, Epidemiology, and Control.Virus research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that causes severe disease in humans and animals and continues to pose a significant global public health threat. Current diagnostic methods primarily rely on detecting CHIKV-specific IgM and IgG antibodies; however, these methods are limited to the humoral immune phase following viral infection.To address the diagnostic gap during the window period before antibody response, we developed two antigen detection assays capable of directly detecting the CHIKV envelope protein (CHIKV-E), enabling early and rapid viral detection. Methods: In this study, 20 nanobodies (Nbs) specifically binding to CHIKV-E protein were screened and identified from a constructed immune nanobody library using phage display technology. These Nbs were fused to human IgG1-Fc and expressed as recombinant Nb-Fc antibodies in Expi293F cells. Subsequently, the preferred Nb-Fc pairs (N055-Fc/N055-mIgG1-Fc and 10G4-Fc) were used to establish double-antibody sandwich ELISA (DAS-ELISA) and Au nanoparticle-based immunochromatographic test strip (AuNP-ICTS) assays. Results: Both the DAS-ELISA and AuNP-ICTS demonstrated high sensitivity for CHIKV-E. The two assays also exhibited exclusive specificity for CHIKV-E, showing no cross-reactivity with envelope proteins from four related alphaviruses or two co-circulating flaviviruses. Epitope mapping revealed that nanobodies N055 and 10G4 recognized distinct linear epitopes: N055 targets E1 Domain II, whereas 10G4 recognizes the E1 fusion loop with additional interactions in E1 Domain II and E2 Domain B. Quantitative sensitivity analysis indicated that both DAS-ELISA and AuNP-ICTS effectively detect CHIKV-E in serum, with limits of detection (LoD) of 49 pg/mL and 1.56 ng/mL, respectively-demonstrating superior sensitivity compared with existing antigen detection methods. Notably, the AuNP-ICTS method completes detection within 10 min, significantly improving efficiency. Discussion: Collectively, the developed DAS-ELISA and AuNP-ICTS assays overcome the limitations of conventional IgM/IgG serological methods, providing superior sensitivity and rapid detection capabilities that make them promising diagnostic tools for early CHIKV detection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.